Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

The conversation is about using micro needling and PTD-DBM for hair loss treatment. The user applies PTD-DBM drops on weekdays and performs micro needling weekly.

ET-02 (RS 5441) shows promising results for hair growth, performing better in humans than in mice. There is debate over the effectiveness compared to minoxidil, with some users wanting more detailed data.

GT20029 and pyrilutamide are both androgen antagonists but work differently; GT20029 degrades the androgen receptor, while pyrilutamide blocks DHT from binding. GT20029 is expected to have similar efficacy to CosmeRNA.

A 22-year-old is using 5mg oral minoxidil, 0.5mg dutasteride, and a 1.5mm dermastamp for hair loss, experiencing good results but feeling more sleepy. There is debate about the appropriate dermastamp size, with some suggesting 0.5mm is safer to avoid fibrosis.

Kintor's 1% Pyrilutamide will be released in October/November. The user cannot tolerate finasteride.

The user has been using minoxidil and finasteride without success and is now trying a new product called Arata Mitoactive, which contains the ingredient y100. They plan to review its effectiveness themselves due to a lack of existing reviews.

GT20029 showed significant hair growth and safety in phase II trials, with no adverse sexual events. Users are hopeful but concerned about future costs and systemic effects.

PTD-DBM is being explored for hair regrowth by targeting CXXC5, with clinical trials expected after pre-clinical studies. Users express anticipation and skepticism about its effectiveness.

SCUBE3, a protein linked to hair growth in moles, was discovered over 25 years ago and is being developed by Amplifica for potential hair loss treatment. Concerns exist about SCUBE3's association with cancer, as it is a protein that promotes cell growth, which could potentially trigger cancer development if used for hair growth therapy.

GT20029 is discussed as a potential treatment for androgenetic hair loss by targeting androgen receptors, unlike finasteride which reduces DHT broadly. Concerns include its effectiveness, genetic variations in androgen receptors, and availability, with some skepticism about its potential as a true alternative.

PTD-DBM is a Korean-developed treatment for hair loss, with limited information available and some users testing it personally. A user purchased PTD-DBM for $115 and plans to test it on their temples, but its effectiveness and authenticity remain uncertain.

TDM-105795 is a potential hair growth stimulant that works differently from minoxidil and could be used alongside it for enhanced growth. It completed phase 2 trials in 2024, with a medium to high chance of release in 2026, but lacks recent updates or phase 3 trial information.

TDM-105795 showed better efficacy and safety in trials for hair loss, with a higher hair count improvement compared to GT20029 and HMI 115, but it's not as widely discussed. The user is questioning why this is the case.

The user achieved impressive hair regrowth using 1mg finasteride and topical minoxidil, and is now adding dutasteride due to recent diffuse thinning. They experienced initial side effects with finasteride but no longer have issues.

A 35-year-old male is experiencing diffuse thinning and is using finasteride, topical minoxidil, and dutasteride. He is considering a hair transplant but is advised to wait and continue with medications for now.

CB-03-01 is considered a failed treatment for hair loss, with future hopes pinned on PP-405 and GT-20029, expected by 2030. Alternatives like hair transplants and SMP are discussed, while some users express frustration over the slow progress of treatments like Breezula.

Dutasteride mesotherapy in women with metabolic syndrome accelerated hair loss after initial regrowth, while women without metabolic syndrome saw continuous regrowth. The user with mild insulin resistance is hesitant to try topical dutasteride and seeks experiences from others with insulin resistance.

The user is using topical minoxidil and finasteride with good results and is considering adding stemoxydine 5% to their regimen. Another user suggests trying it if financially feasible, as results can vary.

There are no updates on GT20029, and concerns about its safety and effectiveness remain. The phase III trial has not started, and there are no new studies or data releases.

The user reports progress in hair regrowth using topical finasteride/minoxidil, microneedling, topical dutasteride, latanoprost, and MSM supplements. They express frustration over the lack of interaction on progress posts compared to trivial topics.

Amplifica has not provided updates on SCUBE3 and AMP-303, raising concerns about their trial outcomes. Users also mention other treatments like Minoxidil, finasteride, RU58841, PP405, and ET-03.

The user has tried topical Minoxidil and oral Minoxidil for beard and scalp hair growth with minimal results, and has been on Finasteride for 7 months with stabilized scalp hair but no facial hair improvement. They are considering using a SULT1A1 enzyme booster to enhance results and are questioning its effectiveness without concurrent topical Minoxidil application.

Mallia Aesthetics has developed MAL-838, a hormone-free product derived from sCD83, which stimulates hair growth without disrupting the skin microbiome. sCD83 promotes hair growth by activating hair follicles and preventing cell death, offering a localized treatment without systemic side effects.

A 28-year-old male experienced significant hair regrowth at the temples using 5mg Minoxidil and 0.5mg Dutasteride daily since January, with no side effects. He plans to continue the treatment indefinitely to maintain results.

The user reports that MSM supplementation has thickened their hair strands while using finasteride and topical minoxidil. They also take zinc, copper, B-complex, vitamin C, vitamin D3, and K2, and plan to add omega-3, magnesium, astaxanthin, and pterostilbene.

The user must stop minoxidil due to a heart murmur and is considering alternatives like nanoxidil or stemoxydine while continuing dutasteride. Suggestions include adding pyrilutamide and alfatradiol or switching to topical minoxidil at a lower concentration.

GT20029 is a topical treatment that degrades androgen receptors to prevent hair thinning and loss, potentially offering fewer side effects than systemic treatments like finasteride. Concerns include its impact on hair texture and potential systemic effects, with market availability speculated in 3 to 5 years.

Clascoterone, a topical anti-androgen, is generating interest for potentially fewer systemic side effects. Users are curious about its effectiveness and details like concentration and duration of use.

A 21-year-old male diagnosed with telogen effluvium and male pattern baldness started taking finasteride, which initially slowed hair shedding and slightly thickened hair. The doctor recommended iron and vitamin D supplements, and the user is considering minoxidil but wants to stabilize shedding first.

GT20026 is discussed as a potential treatment for hair loss that targets androgen receptors without affecting hormone levels, but it may not promote significant regrowth. It is expected to be available by 2028, with other treatments like Breezula and Clascoterone also mentioned.